AIM
CRVS icon

Avity Investment Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Avity Investment Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$401K Sell
34,800
-2,350
-6% -$32.7K 0.03% 97
2026
Q2 		$555K Buy
37,150
+3,950
+12% +$54.8K 0.04% 83
2026
Q1 		$486K Buy
33,200
+520
+2% +$8.3K 0.04% 85
2025
Q4 		$252K Hold
32,680
– – 0.02% 99
2025
Q3 		$241K Hold
32,680
– – 0.02% 100
2025
Q2 		$131K Hold
32,680
– – 0.01% 108
2025
Q1 		$104K Buy
32,680
+3,000
+10% +$14.1K 0.01% 102
2024
Q4 		$159K Buy
29,680
+2,100
+8% +$15.7K 0.01% 107
2024
Q3 		$146K Buy
27,580
+16,000
+138% +$57.5K 0.01% 110
2024
Q2 		$21.1K Buy
11,580
+100
+0.9% +$186 ﹤0.01% 107
2024
Q1 		$20.4K Hold
11,480
– – ﹤0.01% 111
2023
Q4 		$20.2K Hold
11,480
– – ﹤0.01% 109
2023
Q3 		$16.8K Buy
+11,480
New +$24.3K ﹤0.01% 87

Other funds holding CRVS

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Eastern Bank
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Avity Investment Management's CRVS Position: Q3 2026 in Review

Avity Investment Management reduced its Corvus Pharmaceuticals (CRVS) stake by 6.3% in Q3 2026, selling an estimated $32.7K and leaving 34,800 shares worth $401K. The position accounts for 0.03% of the portfolio, ranked #97.

Avity Investment Management first reported a position in CRVS in Q3 2023 and has held it in 13 quarters since. The position peaked at $555K in Q2 2026. 6 funds tracked by Wall St. Rank hold CRVS as of Q3 2026.

  • Avity Investment Management held 34,800 shares of Corvus Pharmaceuticals worth $401K as of Q3 2026.
  • Avity Investment Management sold 2,350 Corvus Pharmaceuticals shares in Q3 2026, an estimated $32.7K.
  • Corvus Pharmaceuticals made up 0.03% of Avity Investment Management's portfolio in Q3 2026, its #97 holding.
  • Avity Investment Management first reported a position in Corvus Pharmaceuticals in Q3 2023 and has held it in 13 quarters since.
  • Avity Investment Management's Corvus Pharmaceuticals position peaked at $555K in Q2 2026.
  • 6 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2026.

Based on Avity Investment Management's 13F filing for Q3 2026, filed 9 Oct 2026.